Support Article
BATReset Safety and Oversight
BATReset is framed as a safety-first, provider-guided cycle. The goal is to support clearance rhythm while keeping decisions tied to eligibility review, laboratory monitoring, and follow-up data.
Clinical Oversight and Supervision
BATReset is provider-guided and reviewed in clinical context.
Eligibility, suitability, and follow-up planning are based on provider review of individual health context and monitoring data.
Supervision includes:
- Provider-guided suitability review
- Baseline and follow-up monitoring
- Ongoing check-ins as needed
- Adjustment of follow-up planning based on trend patterns
Self-directed use is not the intended use model.
Laboratory and Monitoring Requirements
Before beginning a short reset cycle, baseline laboratory and biomarker review may be used to support safer, individualized planning.
During and after the cycle, follow-up measurements may be reviewed to support trend-based decisions.
These review steps are intended to support a safer and more individualized monitoring approach.
Medication and Lab Independence
BATWatch is lab- and pharmacy-agnostic. Medications are prescribed by treating providers and dispensed by independent pharmacies, with cost-transparency language used to reduce surprise billing patterns.
Expected Physiological Responses
Individual responses to short reset cycles can vary.
This is a provider-guided process where short-term adjustments may occur and should be discussed during follow-up review.
Common, temporary responses may include:
- Mild fatigue or decreased appetite
- Temporary sleep pattern changes
- Mild headache or lightheadedness
- Other temporary changes discussed with a provider
Reported effects should be reviewed in context rather than interpreted in isolation.
Providers monitor all reported effects to ensure safety and adjust pacing if necessary.
Potential Side Effects and Risk Mitigation
Any medication decision should be reviewed by a licensed provider in context.
The approach emphasizes careful review, follow-up, and trend-based adjustment.
Rare but possible side effects may include:
- Temporary lipid or glucose elevation
- Hormonal fluctuation (e.g., mild cortisol change)
- Gastrointestinal discomfort
- Minor rash or transient immune response
If symptoms occur, providers may adjust follow-up planning based on clinical judgment.
Decisions are individualized and based on provider-guided review.
Contraindications
Suitability for a short reset cycle is determined by provider review of medical history and current health context.
Providers screen relevant factors before recommending participation.
Safety always outweighs potential benefit.
Long-Term Safety Record
Ongoing safety review is part of the monitoring framework.
Safety interpretation is tied to provider review, follow-up data, and individual context.
Safety information is reviewed over time to support continuous improvement in monitoring practices.
Ongoing Monitoring After Each Cycle
Each patient may complete follow-up BATCheck review after a cycle.
This helps assess whether biological patterns appear steady after the cycle.
Provider teams review:
- Post-cycle trend patterns
- Follow-up biomarker context
- Patient-reported changes
- BATScore direction over time
If drift patterns reappear, providers may adjust future follow-up planning accordingly.